Precedence Research analyzes the new publication titled “Pharmaceutical Logistics Market (By Type: Cold Chain Logistics and Non-cold Chain Logistics; By Component: Storage and Transportation) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030”, As per the report, the pharmaceutical logistics market size was US$ 7.9 billion in 2020. It is projected to grow US$ 16.23 billion by 2030 at a CAGR of 7.5% in the forecast period.
Download the FREE Sample Report (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1442
Market Overview
A recent study by Precedence Research on the pharmaceutical logistics market offers a forecast for 2021 and 2030. The study analyzes crucial trends that are currently determining the growth of the pharmaceutical logistics market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of pharmaceutical logistics. The study also provides the dynamics that are responsible for influencing the future status of this market over the forecast period.
A detailed assessment of the pharmaceutical logistics market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the pharmaceutical logistics market along with their product portfolio enhances the reliability of this comprehensive research study.
Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market
Key Points
- Primary Research
- Secondary Research
- Market Size Estimation
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Macroeconomic Indicators
- Technology Trends and Assessment
- Market Factor Analysis
- Porter’s Five Forces Analysis
- Bargaining Power Of Suppliers
- Bargaining Power Of Buyers
- Threat Of New Entrants
- Threat Of Substitutes
- Intensity Of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
Research Methodology
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, the structure of the market participants and industry's competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
Industry participants involved in this research study include:
- CEOs, VPs, market intelligence managers
- Procuring and national sales managers technical personnel, distributors and resellers
- Research analysts and key opinion leaders from various domains
Competition Landscape
In the final section of the report on the global pharmaceutical logistics market, a 'dashboard view' of the companies has been provided to compare the current market scenario and the contribution of companies to the global pharmaceutical logistics market. Moreover, the report is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to segments of the global market. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on an in-depth assessment of their capabilities and success in the pharmaceutical logistics marketplace.
Some of the prominent players in the global pharmaceutical logistics market include:
- ICON Plc
- Pharmaceutical Product Development LLC
- Parexel International Corporation
- IQVIA
- Quanticate
- Bioclinica
- Covance Inc.
- Accenture Plc
- IBM Corporation
- Novartis
Market Segmentation
Segments of the global pharmaceutical logistics market have been analyzed in terms of their market share to understand an individual segment’s relative contribution to market growth. This detailed level of information is important for identifying key trends in the global pharmaceutical logistics market.
Market Segments as below:
By Clinical Trial Phase
- Preclinical Phase I
- Phase II
- Phase III
- Phase IV
By Service Provider
- In-house
- Contract Outsourcing
By End User
- Hospitals
- Pharmaceutical Companies
- Others
By Therapeutic Area
- Oncology
- Neurology
- Cardiology
- Respiratory Systems
- Others
By Type
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
By Process Flow
- Case Data Management
- Case Logging
- Case Data Analysis
- Medical Reviewing & Reporting
- Signal Detection
- Adverse Event Logging
- Adverse Event Analysis
- Adverse Event Review & Reporting
- Risk Management System
- Risk Evaluation System
- Risk Mitigation System
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Process Flow Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmacovigilance Market
5.1. COVID-19 Landscape: Pharmacovigilance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmacovigilance Market, By Clinical Trial Phase
8.1. Pharmacovigilance Market, by Clinical Trial Phase Type, 2021-2030
8.1.1. Preclinical Phase I
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Pharmacovigilance Market, By Service Provider Type
9.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030
9.1.1. In-house
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Contract Outsourcing
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Pharmacovigilance Market, By End User
10.1. Pharmacovigilance Market, by End User Type, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Pharmaceutical Companies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Pharmacovigilance Market, By Therapeutic Area
11.1. Pharmacovigilance Market, by Therapeutic Area Type, 2021-2030
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Neurology
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Cardiology
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Respiratory Systems
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Pharmacovigilance Market, By Type
12.1. Pharmacovigilance Market, by Type, 2021-2030
12.1.1. Spontaneous Reporting
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Intensified ADR Reporting
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Targeted Spontaneous Reporting
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Cohort Event Monitoring
12.1.4.1. Market Revenue and Forecast (2017-2030)
12.1.5. EHR Mining
12.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Pharmacovigilance Market, By Process Flow
13.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030
13.1.1. Case Data Management
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Signal Detection
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Risk Management System
13.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Pharmacovigilance Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.1.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.1.3. Market Revenue and Forecast, by End User (2017-2030)
14.1.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.1.5. Market Revenue and Forecast, by Type (2017-2030)
14.1.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.1.7.3. Market Revenue and Forecast, by End User (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.1.8. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.1.9.3. Market Revenue and Forecast, by End User (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.1.10. Market Revenue and Forecast, by Type (2017-2030)
14.1.11. Market Revenue and Forecast, by Process Flow (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.2.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.2.3. Market Revenue and Forecast, by End User (2017-2030)
14.2.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.2.5. Market Revenue and Forecast, by Type (2017-2030)
14.2.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.2.8.3. Market Revenue and Forecast, by End User (2017-2030)
14.2.9. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.2.10. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.2.11.3. Market Revenue and Forecast, by End User (2017-2030)
14.2.12. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.2.13. Market Revenue and Forecast, by Type (2017-2030)
14.2.14. Market Revenue and Forecast, by Process Flow (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.2.15.3. Market Revenue and Forecast, by End User (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.2.16. Market Revenue and Forecast, by Type (2017-2030)
14.2.16.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.2.17.3. Market Revenue and Forecast, by End User (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.2.18. Market Revenue and Forecast, by Type (2017-2030)
14.2.18.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.3.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.3.3. Market Revenue and Forecast, by End User (2017-2030)
14.3.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.3.5. Market Revenue and Forecast, by Type (2017-2030)
14.3.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.3.8. Market Revenue and Forecast, by Type (2017-2030)
14.3.9. Market Revenue and Forecast, by Process Flow (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.3.10.3. Market Revenue and Forecast, by End User (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.3.11. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.3.12.3. Market Revenue and Forecast, by End User (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Type (2017-2030)
14.3.12.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.3.13.3. Market Revenue and Forecast, by End User (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Type (2017-2030)
14.3.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.4.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.4.3. Market Revenue and Forecast, by End User (2017-2030)
14.4.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.4.5. Market Revenue and Forecast, by Type (2017-2030)
14.4.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.4.8. Market Revenue and Forecast, by Type (2017-2030)
14.4.9. Market Revenue and Forecast, by Process Flow (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.4.10.3. Market Revenue and Forecast, by End User (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.4.11. Market Revenue and Forecast, by Type (2017-2030)
14.4.12. Market Revenue and Forecast, by Process Flow (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.4.13.3. Market Revenue and Forecast, by End User (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Type (2017-2030)
14.4.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.4.14.3. Market Revenue and Forecast, by End User (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Type (2017-2030)
14.4.14.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.5.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.5.3. Market Revenue and Forecast, by End User (2017-2030)
14.5.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.5.5. Market Revenue and Forecast, by Type (2017-2030)
14.5.6. Market Revenue and Forecast, by Process Flow (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.5.7.3. Market Revenue and Forecast, by End User (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.5.8. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.1. Market Revenue and Forecast, by Process Flow (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)
14.5.9.3. Market Revenue and Forecast, by End User (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Process Flow (2017-2030)
Chapter 15. Company Profiles
15.1. ICON Plc
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pharmaceutical Product Development LLC
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Parexel International Corporation
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. IQVIA
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Quanticate
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bioclinica
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Covance Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Accenture Plc
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. IBM Corporation
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Novartis
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Why Buy this Report?
The purpose of Precedence Research's pharmaceutical logistics market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1442
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments